FDA view on approving agents agnostic of cancer site
Biomarker based therapy - the next frontier?
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers.
1st Approval Agnostic of Cancer Site- When a Biomarker Defines the Indication w/ Drs Lemery, Keegan, Pazdur
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication — NEJM
IMO a biomarker leading to drug approval should be defined and validated BEFORE approval
Reflection on the 1st "agnostic" approved #cancer drug & funny that this term is now commonly used in medicine
First FDA Approval Agnostic of #Cancer Site — When a Biomarker Defines the Indication — NEJM
Recall the 1st mAb (Herceptin) & 1st targeted Tx (Gleevac). Now, we have a 1st Tx agnostic to histology.
Perspective: First FDA Approval Agnostic of #Cancer Site — When a Biomarker Defines the Indication
Game Changer: First FDA Approval Agnostic of Cancer Site-When a Biomarker Defines the Indication